Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.60 Average Price Target from Analysts

Shares of Sight Sciences, Inc. (NASDAQ:SGHT) have earned a consensus rating of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $4.60.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Wednesday, April 10th.

Insider Activity at Sight Sciences

In related news, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $51,424.84. Following the transaction, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now directly owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 12,571 shares of Sight Sciences stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $63,860.68. Following the completion of the transaction, the chief executive officer now owns 5,750,729 shares of the company’s stock, valued at $29,213,703.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,129 shares of company stock worth $173,375. 27.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC acquired a new position in shares of Sight Sciences during the fourth quarter worth approximately $54,000. FMR LLC boosted its position in shares of Sight Sciences by 484.6% during the second quarter. FMR LLC now owns 4,864 shares of the company’s stock worth $44,000 after buying an additional 4,032 shares during the period. US Bancorp DE acquired a new position in shares of Sight Sciences during the fourth quarter worth approximately $27,000. Cubist Systematic Strategies LLC acquired a new position in shares of Sight Sciences during the third quarter worth approximately $37,000. Finally, Barclays PLC boosted its position in shares of Sight Sciences by 540.7% during the fourth quarter. Barclays PLC now owns 5,850 shares of the company’s stock worth $72,000 after buying an additional 4,937 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $5.23 on Wednesday. The company has a market cap of $259.15 million, a price-to-earnings ratio of -4.59 and a beta of 2.83. The stock has a 50 day simple moving average of $4.80 and a 200-day simple moving average of $4.04. Sight Sciences has a 12-month low of $1.04 and a 12-month high of $11.20. The company has a current ratio of 13.29, a quick ratio of 12.65 and a debt-to-equity ratio of 0.26.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.13. The firm had revenue of $18.75 million during the quarter, compared to the consensus estimate of $18.70 million. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. During the same period last year, the business posted ($0.35) EPS. On average, equities analysts forecast that Sight Sciences will post -1.04 EPS for the current year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.